Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 615

1.

Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2019 Nov 21. pii: haematol.2019.229781. doi: 10.3324/haematol.2019.229781. [Epub ahead of print]

2.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT.

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A.

Blood Cancer J. 2019 Nov 18;9(12):88. doi: 10.1038/s41408-019-0251-3.

3.

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.

Hayden PJ, Iacobelli S, Pérez-Simón JA, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver FJ, Veelken JH, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Henri Bourhis J, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger N.

Eur J Haematol. 2019 Nov 18. doi: 10.1111/ejh.13352. [Epub ahead of print]

PMID:
31737951
4.

DAMIAN: an open source bioinformatics tool for fast, systematic and cohort based analysis of microorganisms in diagnostic samples.

Alawi M, Burkhardt L, Indenbirken D, Reumann K, Christopeit M, Kröger N, Lütgehetmann M, Aepfelbacher M, Fischer N, Grundhoff A.

Sci Rep. 2019 Nov 14;9(1):16841. doi: 10.1038/s41598-019-52881-4.

5.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox CP, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J; French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties.

Bone Marrow Transplant. 2019 Nov 7. doi: 10.1038/s41409-019-0742-7. [Epub ahead of print]

PMID:
31700137
6.

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis.

Schultze-Florey CR, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke GN, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak GW; EBMT Transplant Complications Working Party (TCWP).

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0738-3. [Epub ahead of print] No abstract available.

PMID:
31695171
7.

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon MJP, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin M.

Biol Blood Marrow Transplant. 2019 Oct 21. pii: S1083-8791(19)30672-X. doi: 10.1016/j.bbmt.2019.10.015. [Epub ahead of print]

PMID:
31647984
8.

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.

Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, Remenyi P, Passweg J, Beelen DW, Aljurf M, Kröger N, Labussière-Wallet H, Perić Z, Giebel S, Nagler A, Mohty M.

J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.

9.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis.

Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, Bonifazi F, Meijer E, Itälä-Remes M, Marková M, Solano C, Kröger N.

JAMA Oncol. 2019 Oct 17. doi: 10.1001/jamaoncol.2019.3541. [Epub ahead of print]

PMID:
31621796
10.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16185. [Epub ahead of print]

PMID:
31612473
11.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.

Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0702-2. [Epub ahead of print]

PMID:
31562398
12.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.

Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner HW, Pohlreich D, Hayden P, Basak GW, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N.

Bone Marrow Transplant. 2019 Sep 18. doi: 10.1038/s41409-019-0676-0. [Epub ahead of print]

PMID:
31534192
13.

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.

Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC.

Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162.

PMID:
31511238
14.

Identification of proteins in the adhesive trails of the diatom Amphora coffeaeformis.

Lachnit M, Buhmann MT, Klemm J, Kröger N, Poulsen N.

Philos Trans R Soc Lond B Biol Sci. 2019 Oct 28;374(1784):20190196. doi: 10.1098/rstb.2019.0196. Epub 2019 Sep 9.

PMID:
31495312
15.

[Current recommendations for the systemic treatment of metastatic renal cell carcinoma].

Kröger N, Merseburger AS, Bedke J.

Aktuelle Urol. 2019 Dec;50(6):606-611. doi: 10.1055/a-0972-0788. Epub 2019 Sep 4. German.

PMID:
31486060
16.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.

Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.

PMID:
31477550
17.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.

Andersen NS, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede LC, Schönland S, Kröger N, Schetelig J; CLL subcommittee, Chronic Malignancies Working Party.

J Cancer Res Clin Oncol. 2019 Nov;145(11):2823-2834. doi: 10.1007/s00432-019-03014-x. Epub 2019 Aug 29.

PMID:
31468122
18.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kröger N, Mohty M, Gratwohl A; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2019 Aug 27. doi: 10.1038/s41409-019-0624-z. [Epub ahead of print]

PMID:
31455899
19.

Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.

Mannina D, Gagelmann N, Badbaran A, Ditschkowski M, Bogdanov R, Robin M, Cassinat B, Heuser M, Shahswar R, Thol F, Beelen D, Kröger N.

Eur J Haematol. 2019 Dec;103(6):552-557. doi: 10.1111/ejh.13318. Epub 2019 Sep 16.

PMID:
31446640
20.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.

Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0544-3. [Epub ahead of print]

PMID:
31427719
21.

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin.

Baron F, Galimard JE, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kröger N, Griskevicius L, Wu D, Forcade E, Richard C, Aljurf M, Helbig G, Labussière-Wallet H, Mohty M, Nagler A.

Haematologica. 2019 Aug 14. pii: haematol.2019.227603. doi: 10.3324/haematol.2019.227603. [Epub ahead of print]

22.

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.

Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T.

Leukemia. 2019 Aug 13. doi: 10.1038/s41375-019-0536-3. [Epub ahead of print] No abstract available.

PMID:
31409922
23.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward KN, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2019 Dec;54(12):2060-2071. doi: 10.1038/s41409-019-0627-9. Epub 2019 Jul 30.

PMID:
31363166
24.

Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.

Mannina D, Kröger N.

Drugs. 2019 Sep;79(14):1499-1509. doi: 10.1007/s40265-019-01174-1.

PMID:
31359326
25.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.

Daghia G, Zabelina T, Zeck G, von Pein UM, Christopeit M, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2019 Oct;103(4):370-378. doi: 10.1111/ejh.13294. Epub 2019 Aug 5.

PMID:
31306511
26.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2267-2273. doi: 10.1016/j.bbmt.2019.07.001. Epub 2019 Jul 6.

PMID:
31288096
27.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6.

PMID:
31288095
28.

Control of biosilica morphology and mechanical performance by the conserved diatom gene Silicanin-1.

Görlich S, Pawolski D, Zlotnikov I, Kröger N.

Commun Biol. 2019 Jun 28;2:245. doi: 10.1038/s42003-019-0436-0. eCollection 2019.

29.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5.

PMID:
31284069
30.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y.

Biol Blood Marrow Transplant. 2019 Oct;25(10):2008-2016. doi: 10.1016/j.bbmt.2019.06.028. Epub 2019 Jul 1.

PMID:
31271884
31.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M.

Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3.

PMID:
31270102
32.

Induction, Bridging, or Straight Ahead: The Ongoing Dilemma of Allografting in Advanced Myelodysplastic Syndrome.

Kröger N.

Biol Blood Marrow Transplant. 2019 Aug;25(8):e247-e249. doi: 10.1016/j.bbmt.2019.06.016. Epub 2019 Jun 20. No abstract available.

PMID:
31229640
33.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Oct;25(10):1975-1983. doi: 10.1016/j.bbmt.2019.05.037. Epub 2019 Jun 7.

PMID:
31181255
34.

Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT.

Ruutu T, van der Werf S, van Biezen A, Backman JT, Peczynski C, Kröger N, Mohty M, Nagler A, Montoto S, Langebrake C, Niederwieser D, Peric Z, Koenecke C, Duarte RF, Basak G.

Bone Marrow Transplant. 2019 Dec;54(12):2013-2019. doi: 10.1038/s41409-019-0579-0. Epub 2019 Jun 3.

PMID:
31160806
35.

Pedobarography shows no differences in gait after talar fractures.

Fenwick A, Kröger N, Jovic S, Hölscher-Doht S, Meffert R, Jansen H.

Technol Health Care. 2019 May 10. doi: 10.3233/THC-191667. [Epub ahead of print]

PMID:
31104035
36.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis.

Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein UM, Janson D, Ayuk F, Kröger N.

Br J Haematol. 2019 Aug;186(3):484-489. doi: 10.1111/bjh.15952. Epub 2019 May 15.

PMID:
31090920
37.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani BN, Mohty M, Nagler A.

J Hematol Oncol. 2019 Apr 25;12(1):44. doi: 10.1186/s13045-019-0727-4.

38.

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.

Cremers EMP, de Witte T, de Wreede L, Eikema DJ, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagkos D, Itälä-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt ZN, Anagnostopoulos A, Jindra P, Robin M, Kröger N.

Leuk Lymphoma. 2019 Oct;60(10):2404-2414. doi: 10.1080/10428194.2019.1594215. Epub 2019 Apr 18.

39.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
40.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J.

Ann Hematol. 2019 Jul;98(7):1755-1763. doi: 10.1007/s00277-019-03669-z. Epub 2019 Apr 16.

PMID:
30993417
41.

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.

Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, Sanz J, Stuhler G, Bosi A, Kröger N, Van Lint MT, Ganser A, Forcade E, Mohty M, Gluckman E, Nagler A.

Blood Cancer J. 2019 Apr 12;9(4):46. doi: 10.1038/s41408-019-0204-x.

42.

[Pancytopenia of unknown origin in a 52-year-old patient].

Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C.

Internist (Berl). 2019 Aug;60(8):867-870. doi: 10.1007/s00108-019-0596-5. German.

PMID:
30969356
43.

Influence of design and postprocessing parameters on the degradation behavior and mechanical properties of additively manufactured magnesium scaffolds.

Kopp A, Derra T, Müther M, Jauer L, Schleifenbaum JH, Voshage M, Jung O, Smeets R, Kröger N.

Acta Biomater. 2019 Oct 15;98:23-35. doi: 10.1016/j.actbio.2019.04.012. Epub 2019 Apr 6.

PMID:
30959185
44.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019.

Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Oct;54(10):1525-1552. doi: 10.1038/s41409-019-0516-2. Epub 2019 Apr 5.

PMID:
30953028
45.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.

PMID:
30930192
46.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

47.

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

Ye R, Kundrapu S, Gerson SL, Driscoll JJ, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e213-e220. doi: 10.1016/j.clml.2018.12.022. Epub 2019 Jan 3.

PMID:
30878316
48.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N.

Haematologica. 2019 Apr;104(4):659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14. Review.

49.

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.

Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D.

Bone Marrow Transplant. 2019 Oct;54(10):1662-1667. doi: 10.1038/s41409-019-0498-0. Epub 2019 Mar 4.

PMID:
30833743
50.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.

Kröger N, Eikema DJ, Köster L, Beelen D, de Wreede LC, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M; Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation.

Br J Haematol. 2019 May;185(4):725-732. doi: 10.1111/bjh.15819. Epub 2019 Feb 28.

PMID:
30820933

Supplemental Content

Loading ...
Support Center